VC-backed Kite Pharma unveils IPO

Kite Pharma has launched its IPO after pricing its 7.5 million shares at $17 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “KITE.” Jefferies, Credit Suisse Securities (USA) and Cowen and Company are the lead underwriters. Based in Santa Monica, Calif., Kite Pharma is a biopharmaceutical firm focused on treating cancer. Kite Pharma’s backers include Alta Partners and TPG Capital.


Ignyta taps TPG Capital’s Chacko as CFO

Ignyta has hired Dr. Jacob Chacko as chief financial officer. He replaces Zachary Hornby, who has become the firm’s chief operating officer. Previously, Chacko worked at TPG Capital where he served as a vice president focused mostly on healthcare and digital media. Based in San Diego, Calif., Ignyta is a biotech firm that is developing precision medicine focused on treating cancer patients.

PEHUB Community

Join the 12505 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget